• Home
  • PR



게시물 상세
OliX Announces FDA Clearance of the Phase 2a Clinical Trial IND for Hypertrophic Scars
Date : 2020-11-13     View : 530

OliX Pharmaceuticals Announces FDA Clearance of the IND to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial for Hypertrophic Scars


-Potential first-in-class treatment for hypertrophic scars with no FDA-approved medicines to-date

-Phase 2a trial follows the successful completion of OliX's Phase 1 trial in the U.K in November 2019

-OliX retains global rights to develop and commercialize OLX10010 outside Asia


Learn more: https://news.yahoo.com/olix-pharmaceuticals-announces-fda-clearance-140200870.html


Source _ OliX Pharmaceuticals

Prev OliX Pharmaceuticals Announces Completion of $37.2 Million Capital Raise
Next OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa